The stratification of FTD individuals according to putative tau pathology subtypes will represent an essential utility for emerging treatments with antibodies and antisense oligonucleotides targeting tau species,50,51 which would be more specific for either 3RT or 4RT. The gene discussed is MAPT; the disease is frontotemporal dementia.